2026-07-08 · leptin, ghrelin, appetite hormones, hunger, weight loss maintenance, endocrinology · 20 min read

What is the main hunger hormone?

Ghrelin is the main circulating hunger hormone. It is secreted mostly by the stomach, rises before meals, falls after eating, and directly activates AgRP neurons in the hypothalamic arcuate nucleus to drive appetite (Nakazato 2001; Wren 2001). Ghrelin infusion in humans reliably increases food intake in a lab setting by ~30% (Wren 2001 J Clin Endocrinol Metab). But hunger is not a one-hormone system — leptin, PYY, GLP-1, CCK, and insulin all feed into the same circuit, and dieting shifts the balance so that hunger stays elevated for at least 12 months post-loss.

Does 'leptin resistance' cause obesity, and can I fix it with a supplement?

Leptin resistance is a real phenomenon — obese individuals have high circulating leptin (Considine 1996) but a reduced central response to it, similar in shape to insulin resistance in type 2 diabetes. What it is not is a condition treatable with an over-the-counter 'leptin support' pill. Metreleptin (a leptin analog) works only for congenital leptin deficiency and generalized lipodystrophy (Farooqi 1999); in the general-obesity trials (Heymsfield 1999) it produced small effects because most people already have high leptin. Consumer 'leptin resistance protocols' are marketing, not medicine.

How much does leptin drop after weight loss and for how long?

In Sumithran 2011 (N Engl J Med), leptin fell approximately 65% within 8 to 10 weeks of a moderate 10% weight loss and remained roughly 30-40% below baseline at 12 months even after weight stabilization. Ghrelin was elevated by around 20% at the same 12-month mark. PYY and GLP-1 were suppressed. This 'hungry hormone' pattern is a big part of why maintenance is biologically harder than the loss phase — the diet ended, but the body's hunger drive did not.

Do GLP-1 medications work by mimicking a natural hormone?

Yes. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are pharmacological analogs of GLP-1 (with tirzepatide adding a GIP action). They act on the same central GLP-1 receptors that endogenous GLP-1 from ileal L-cells targets, but at drug-level exposures the body cannot normally produce. That is why they lower the defended set point in a way that dietary intervention alone rarely does — you can read more in our GLP-1 weight loss overview.

Why do I feel hungrier when I do not sleep enough?

Because short sleep raises ghrelin and lowers leptin. Taheri 2004 in PLOS Medicine showed adults sleeping under 5 hours had ~15% higher ghrelin and ~15% lower leptin than those sleeping 8 hours. Spiegel 2004 in Annals of Internal Medicine confirmed the effect in a controlled 2-night sleep-restriction trial, with subjects reporting increased hunger and preference for calorie-dense foods. If you want a lever with population-scale effect size on appetite hormones, getting 7 to 9 hours of sleep is one of the strongest.

Does intermittent fasting 'reset' leptin sensitivity?

There is no good evidence for a leptin-sensitivity reset from any short-term dietary pattern, including intermittent fasting or time-restricted eating. Time-restricted eating may align meal-timing hormone rhythms and modestly reduce caloric intake for some people, but there is no controlled trial showing it restores central leptin sensitivity in obesity. The wellness-industry claim that a 30-day fasting protocol 'fixes leptin resistance' is not supported by peer-reviewed data.

How does bariatric surgery affect these hormones?

Roux-en-Y gastric bypass (RYGB) drops ghrelin dramatically — Cummings 2002 in NEJM showed roughly a 72% reduction in circulating ghrelin post-RYGB versus diet-only weight loss. RYGB and sleeve gastrectomy also produce large increases in postprandial GLP-1 and PYY. That combined hormone shift — low ghrelin, high satiety signals — is a large part of why bariatric surgery produces more durable weight loss than lifestyle intervention alone, not simply 'a smaller stomach'.

Is insulin really the master hormone of obesity?

No. The carbohydrate-insulin model treats insulin as the primary driver of fat storage, but the human evidence does not support that framing. Hall 2015 in Cell Metabolism ran a metabolic-ward isocaloric comparison of low-carb vs low-fat diets and found no meaningful fat-loss advantage for the low-carb, insulin-lowering arm. Insulin is one of six appetite-regulating signals — not the master switch. It matters, especially in insulin resistance and type 2 diabetes, but it does not override the coordinated multi-hormone system that leptin, ghrelin, PYY, GLP-1, and CCK build together.

Leptin, Ghrelin, and Hunger Hormones: What Actually Drives Appetite While You’re Losing Weight

Quick answer: Appetite is not run by a single hormone — it is a coordinated system of six. Leptin from fat cells tells the brain how much energy is in long-term storage. Ghrelin from the stomach drives short-term hunger. PYY, GLP-1, and CCK from the gut send meal-to-meal satiety signals. Insulin contributes short-term satiety through central receptors. When you lose weight, the whole system shifts to defend the old weight: Sumithran 2011 in the New England Journal of Medicine showed leptin drops ~65% within 8-10 weeks and stays suppressed for at least 12 months, ghrelin rises ~20% and stays elevated, and PYY and GLP-1 are reduced. That “hungry hormone” pattern is the biology of maintenance — and it is why protein-first eating, fiber and volume, 7-9 hours of sleep, moderate deficits, and (for those who qualify) GLP-1 pharmacotherapy or bariatric surgery are the tools that actually work. Consumer “leptin resistance protocols” and “ghrelin-blocker” supplements are marketing, not medicine.

Who this is for — and who it is not for

This article is for adults who want an honest read on what their appetite hormones are actually doing during weight loss, why hunger stays elevated long after a diet ends, and which levers change the picture. It is written for the reader who has seen “reset your leptin” and “block your ghrelin” claims online and wants to know which of them survive peer review.

It is not a substitute for endocrinology evaluation. If you have unexplained rapid weight loss or gain, suspected pituitary or thyroid disease, a diagnosed eating disorder, or you are considering GLP-1 pharmacotherapy or bariatric surgery, the appropriate next step is a physician — endocrinology, obesity medicine, or bariatric surgery, depending on the presentation. Congenital leptin deficiency is a rare genetic diagnosis (see the Farooqi 1999 case) and is not something a home test kit can determine.

If you are in crisis with hunger-related suicidal thoughts during severe restriction, call or text 988 for the Suicide & Crisis Lifeline. If you are worried about a possible eating disorder, contact the National Eating Disorders Association helpline at 1-800-931-2237 or text “NEDA” to 741741.

The 6 appetite hormones — a primer

Two framings worth locking in early:

• Hunger is not one hormone. Any article that reduces appetite to “ghrelin, the hunger hormone” or “leptin, the master hormone” is oversimplifying. The hypothalamic arcuate nucleus integrates all six signals into a single output.
• Leptin resistance is a real physiological state, not a supplement diagnosis. Obese individuals have high leptin, not low — see Considine 1996 — and the treatment problem is central sensitivity, not peripheral supply.

The 4-driver mechanism — how the system actually works

1. Long-term energy stores — leptin tells the brain how much fat is in reserve

Leptin is secreted by adipocytes in rough proportion to fat mass. It travels to the hypothalamus and binds receptors on POMC neurons in the arcuate nucleus, which release alpha-MSH and drive satiety. It simultaneously inhibits AgRP neurons, which drive hunger. Circulating leptin is the primary long-term signal of “how full is the tank.”

When the tank drops — when you lose fat mass — leptin falls fast, often disproportionately to the actual fat loss. The hypothalamus reads the low leptin signal as a starvation signal and responds by raising hunger, lowering thyroid output (slowing RMR — see our adaptive thermogenesis and metabolic adaptation guide for the RMR side), reducing non-exercise activity, and increasing the reward value of food.

2. Short-term meal signaling — ghrelin, CCK, PYY, and GLP-1 set meal-to-meal appetite

Ghrelin rises in the hours before a scheduled meal and falls after eating. It is the main circulating pre-meal hunger driver. Nakazato 2001 in Nature established the AgRP-driven mechanism, and Wren 2001 in the Journal of Clinical Endocrinology & Metabolism showed that IV ghrelin in humans reliably increases short-term food intake by ~30%.

CCK is the earliest post-meal satiety signal — released by duodenal I-cells within minutes of nutrient delivery, activating vagal afferents that project to the brainstem. PYY (3-36) and GLP-1 come later, from the ileum and colon, when nutrients reach the distal gut. This is the ileal brake — the reason a fiber-rich meal that reaches the distal small intestine intact produces more prolonged satiety than a rapidly absorbed refined-carb meal. Batterham 2002 in Nature was the seminal PYY paper, showing that IV PYY reduced short-term food intake by 33% in a controlled human trial.

3. Central integration — POMC and AgRP neurons weight the signals

All six hormones feed into the arcuate nucleus. POMC neurons drive satiety; AgRP neurons drive hunger. Ghrelin activates AgRP; leptin, PYY, GLP-1, insulin, and CCK activate POMC and inhibit AgRP. The output is a single integrated signal that is then relayed to the paraventricular nucleus, brainstem, and higher reward centers.

Rare monogenic disorders that break this circuit — MC4R mutations (Yeo 2000 in Nature Genetics), leptin gene mutations, POMC deficiency — produce severe early-onset obesity and confirm the wiring diagram in humans. These conditions account for a tiny fraction of adult obesity, but they map the circuitry the common condition acts on.

4. Leptin resistance — obesity does not lower leptin, it blunts the response to it

The classic wellness-industry mistake is treating obesity as leptin deficiency. It is not. Considine 1996 in the New England Journal of Medicine measured serum leptin across BMI and found it rose approximately in proportion to fat mass — obese adults had leptin levels three to four times higher than lean controls. The problem is that the central response to that high leptin is blunted.

That is why the general-obesity metreleptin trials (Heymsfield 1999) failed: giving leptin to someone who already has high leptin does not restore the missing signal. Metreleptin does work — brilliantly — for the small number of patients with congenital leptin deficiency or generalized lipodystrophy, where the underlying problem is genuinely not enough hormone. Farooqi 1999 in NEJM is the case that established the treatment for that population. Trying to extrapolate it to common obesity is the mistake.

What weight loss actually does to these hormones

The definitive study is Sumithran 2011 in the New England Journal of Medicine. Fifty overweight or obese adults underwent a 10-week very-low-calorie diet (mean loss 13.5 kg), then were followed for 12 months. The hormone panel at week 10 and again at week 62 (after 12 months of maintenance attempts) tells the story:

• Leptin fell about 65% by the end of the diet and remained roughly 30-40% below baseline at 12 months, even in participants who had partially regained.
• Ghrelin rose about 20% by the end of the diet and remained elevated at 12 months.
• PYY was reduced at 12 months post-diet.
• Endogenous GLP-1 was reduced at 12 months post-diet.
• CCK showed reduced postprandial elevation at 12 months.
• Subjective hunger and appetite ratings were elevated versus baseline at 12 months.

The mechanistic reading: after a diet, the body’s hormonal state defends the pre-diet weight for at least a year. Leptin is low as if you were starved, ghrelin is high as if you were pre-meal, and the satiety signals that would normally counter that (PYY, GLP-1, CCK) are muted. The biology of maintenance is not the biology of loss.

This is not a moral failing, and it is not “damaged metabolism.” It is a coordinated defense of a previously held body weight — the hormonal arm of what set point theory describes at a system level. See our set point theory and weight loss guide for the broader picture and yo-yo dieting and weight cycling for what happens when the hormonal hunger drive repeats across cycles.

Time course, baseline to 5 years post-diet

The 5-step “how to work with, not against, appetite hormones” protocol

There is no supplement that resets these hormones. There are five behavioral levers with real evidence, and two medical options for readers who qualify.

Step 1 — Protein first, at every meal. Protein has the highest satiety-per-calorie of the three macronutrients. Weigle 2005 in the American Journal of Clinical Nutrition ran a controlled trial in which subjects switched to a 30%-protein diet with no other intake instructions — spontaneous caloric intake fell by approximately 440 kcal/day and subjects lost weight without conscious restriction. The satiety mechanism is partly PYY and GLP-1 elevation, partly CCK, and partly the higher thermic effect of protein. See our protein intake for weight loss guide for specific grams targets and food-first tactics.

Step 2 — Fiber and volume — preload salads, soup, and vegetables. Rolls 2004 in Obesity Research showed that a low-energy-density soup preload before an ad libitum lunch reduced total meal energy intake by roughly 20%. Flood 2007 and follow-up work confirmed the effect across preload formats — high-volume, low-calorie foods trigger stretch-receptor and ileal-brake satiety, reducing subsequent intake by around 13% on average. Fiber intake in the 25 to 35 g/day range also feeds gut microbes that produce SCFAs, which further stimulate PYY and GLP-1 release.

Step 3 — Sleep 7 to 9 hours per night. Taheri 2004 in PLOS Medicine measured leptin and ghrelin across sleep duration in a population sample: adults sleeping under 5 hours had approximately 15% lower leptin and 15% higher ghrelin than adults sleeping 8 hours. Spiegel 2004 in the Annals of Internal Medicine confirmed the effect in a controlled 2-night sleep-restriction trial — subjects reported increased hunger and higher preference for calorie-dense foods. If you want a lever with real effect size on appetite hormones that costs nothing, sleep is it. Our sleep, stress, and weight management guide covers the full protocol.

Step 4 — Time-restricted eating, used realistically. Time-restricted eating may align meal-timing hormone rhythms with circadian biology, and for some people it modestly reduces total caloric intake by shrinking the window in which snacking happens. It is not a magic override of the post-diet leptin-ghrelin pattern, and short-term “fasting resets your leptin sensitivity” claims are not evidence-based. Treat it as a mealtiming structure that works if it fits your life, not as a hormone hack. Our meal timing and chrononutrition guide walks the actual signal versus noise.

Step 5 — Consistent moderate deficit, not aggressive restriction. Aggressive deficits worsen the hormonal changes and typically collapse adherence within weeks. A 0.5 to 1% body-weight-per-week loss rate produces smaller adaptive thermogenesis and a smaller hunger-hormone shift than a 2%-per-week crash — see adaptive thermogenesis and metabolic adaptation for the RMR side of that math and the case for slower loss. If you have hit a plateau or find yourself unable to sustain a plan, why am I not losing weight walks the diagnostic tree of tracking drift, hunger biology, and adaptation.

6-row treatment comparison — behavior, drug, and surgery levers

Special situations

Post-bariatric surgery

Cummings 2002 in NEJM — the RYGB paper — is the citation to know. Circulating ghrelin was approximately 72% lower in RYGB patients than in matched diet-only weight-loss controls, and did not show the normal diurnal rise before meals. Foster-Schubert 2005 in the Journal of Clinical Endocrinology & Metabolism extended this by comparing RYGB against vertical banded gastroplasty (a purely restrictive procedure) — the ghrelin drop was specific to RYGB, not to gastric restriction as such. Combined with the large postprandial rise in PYY and GLP-1 after RYGB, this is the hormonal reason bariatric surgery outperforms lifestyle change on durability. See our gastric bypass surgery guide for the clinical picture.

On GLP-1 or GIP+GLP-1 therapy

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) engage the same central GLP-1 receptors that endogenous GLP-1 targets, at exposures far beyond what the body produces. That drug-level activation lowers the defended set point while the medication continues. It does not permanently reset the hormone system — see the discontinuation trials (STEP-4, SURMOUNT-4) for what happens when the drug is stopped. Our GLP-1 weight loss overview is the fuller clinical read.

After stopping a GLP-1

When exogenous GLP-1 exposure ends, endogenous appetite hormones return to their post-diet pattern: low leptin, elevated ghrelin, muted PYY and endogenous GLP-1. The subjective experience is a dramatic hunger surge. This is one of the biggest predictors of rapid regain and one of the reasons GLP-1s are now framed as long-term therapy. See our rebound weight gain after stopping GLP-1 guide for what to plan for.

Sleep-deprived shift workers

Chronic short sleep amplifies the leptin-low / ghrelin-high pattern. Rotating shifts add a circadian disruption on top of the sleep debt, and the appetite-hormone consequences show up as increased snacking, higher preference for calorie-dense foods, and weight gain over time. The mitigation is not “eat less willpower” — it is sleep-schedule engineering and, where possible, blocking blue-light exposure at wake times. Our sleep, stress, and weight management guide covers the shift-worker protocol.

Post-menopause

Estrogen supports central leptin sensitivity in premenopausal women. After menopause, the drop in estradiol tends to shift fat distribution centrally and modestly reduce the appetite-suppressing effect of leptin. That is one of several reasons weight gain around menopause is common. See our menopause and weight loss guide for the fuller endocrine picture, and note that menopausal hormone therapy has been studied for its metabolic effects.

PCOS

Polycystic ovary syndrome commonly features hyperinsulinemia, which interacts with the leptin system — high insulin can worsen leptin resistance at the central level, and the two hormone resistances tend to co-occur. The practical implication is that appetite regulation in PCOS is often harder even at matched body weight, and treatment approaches that address insulin (metformin, weight loss itself, GLP-1s in select patients) tend to also improve satiety. See our PCOS and weight loss guide.

Congenital leptin deficiency

This is the exception that proves the rule. A small number of people carry loss-of-function mutations in the leptin gene and produce essentially no functional leptin. They present with severe hyperphagia and early-onset severe obesity. Farooqi 1999 in NEJM described the metreleptin response in this population — dramatic reduction in food intake and normalization of weight. It is a beautiful demonstration that the leptin signal is causal, and it is completely non-generalizable to typical obesity, where leptin levels are already high.

Weight-loss maintenance

The Sumithran 2011 pattern — leptin low, ghrelin high, satiety hormones suppressed — persists for at least 12 months and, in many individuals, longer. The behavioral phenotype of successful long-term maintainers (National Weight Control Registry data) is high activity, high protein, daily self-monitoring, and structured eating — which reads as “people who organise their week around defending against a persistent hunger drive.” See our weight loss maintenance guide.

6 myths and red flags — and where to draw the line

• “Leptin resistance is why you can’t lose weight — take a leptin supplement.” Wrong on two counts. Obese individuals already have high leptin (Considine 1996), and no over-the-counter “leptin support” pill contains functional leptin or activates its receptor. Metreleptin is an injectable prescription drug for congenital leptin deficiency and generalized lipodystrophy only.
• “Ghrelin blockers on Amazon will suppress your hunger.” No FDA-approved oral ghrelin blocker exists. Products marketed under this label are ordinary appetite-suppressant blends (usually caffeine, glucomannan, fiber, or stimulants) trading on the “ghrelin” search term. See our appetite suppressant supplements guide for what actually is in the bottle.
• “Intermittent fasting resets your leptin sensitivity in 30 days.” Not supported. Time-restricted eating may improve some metabolic markers, but no controlled human trial shows a 30-day IF protocol restores central leptin sensitivity in obesity.
• “You can fix leptin resistance with the right diet in 30 days.” Same issue. Chronic-inflammation reduction and modest weight loss can improve central leptin signaling gradually, but “in 30 days” is a marketing frame, not an endocrinology finding.
• “Insulin is the master hormone of obesity.” Overstated. Hall 2015 in Cell Metabolism ran an isocaloric metabolic-ward comparison of low-carb versus low-fat diets and found no meaningful advantage for the low-insulin arm on fat loss. Insulin is one of six signals — important, especially in insulin resistance, but not the master switch the carbohydrate-insulin model claims.
• “Bariatric surgery works because it shrinks your stomach.” Partly, but mostly no. The hormonal shift — dramatic ghrelin drop after RYGB, elevated postprandial PYY and GLP-1 — is at least as important as restriction. Sleeve gastrectomy also removes the ghrelin-producing gastric fundus, which is a large part of its effect. If it were purely restrictive, purely restrictive procedures (gastric banding, VBG) would work as well as RYGB — they don’t.

Emergency lines to know. If you are having hunger-related suicidal thoughts during severe restriction, call or text 988 for the Suicide & Crisis Lifeline. For suspected disordered eating in yourself or a loved one, NEDA helpline: 1-800-931-2237 or text “NEDA” to 741741. For medication overdose or suspected supplement toxicity, US Poison Control: 1-800-222-1222.

Practical next steps

This week

• Set a protein floor at every meal — aim for 25 to 40 g at breakfast if you tend to under-eat protein early in the day.
• Add a fiber-rich preload (a salad, a broth-based soup, or a raw vegetable snack) before your two largest meals.
• Move bedtime earlier by 30 minutes for 7 straight nights. Track subjective hunger the next day.

Over the next 4 to 12 weeks

• Hold a moderate deficit — 0.5 to 1% of body weight per week — rather than an aggressive one.
• If you’re not losing weight and think it’s willpower, read why am I not losing weight first — the diagnostic tree separates hormone biology from tracking drift.
• If you have a BMI ≥ 30 or ≥ 27 with a comorbidity and want to discuss pharmacotherapy, ask your primary care physician about a referral to an obesity medicine specialist or endocrinology.

Long term

• Assume the leptin-ghrelin gap does not fully close after a large loss. Design your week around defending against a persistent hunger drive, not around waiting for it to go away.
• Prioritise sleep. It is one of the strongest levers on the appetite hormone system, and it costs nothing.

How this article was researched

We reviewed peer-reviewed research on the endocrinology of appetite regulation, including the Sumithran 2011 hormonal-adaptation study, the Cummings 2002 ghrelin work, the Considine 1996 human leptin measurement study, the Nakazato 2001 ghrelin discovery, the Farooqi 1999 congenital leptin deficiency case, the Wren 2001 ghrelin infusion studies, the Batterham 2002 PYY paper, the Rosenbaum 2005 leptin replacement study, and the Weigle 2005 high-protein satiety trial, plus the Taheri 2004 and Spiegel 2004 sleep-and-hormone work and the Rolls 2004 and Flood 2007 fiber and volume trials. Claims are limited to what the peer-reviewed literature supports. Practical recommendations are framed as starting points, not individualised medical advice.